Trials / Completed
CompletedNCT00530595
Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Saitama Medical University · Academic / Other
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Cardiovascular disease is a leading cause of mortality in patients on hemodialysis therapy (HD), accounting for 30 to 50% of all death. Although angiotensin receptor blockers (ARBs) are effective for patients with diabetes and chronic kidney disease in reducing or preventing cardiovascular diseases, there has been no decisive study that demonstrated treatment with ARBs is effective in patients on HD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | candesartan or valsartan or losartan |
Timeline
- First posted
- 2007-09-17
- Last updated
- 2007-09-17
Source: ClinicalTrials.gov record NCT00530595. Inclusion in this directory is not an endorsement.